



# Consultations

## Consultation on the draft 2024/25 Invitation to Tender (for healthcare professionals)

23 July 2024

### Overview

Pharmac | Te Pātaka Whaioranga is seeking feedback from healthcare professionals, medical groups, hospital pharmacies, and other interested parties on the draft 2024/25 Invitation to Tender.

**Consultation closes at 4 pm (New Zealand standard time) on Tuesday 3 September 2024**

Submit feedback through our [online form](#) or email [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

We're particularly interested in feedback on:

- would a brand change for any of the medicines included in the draft tender list be not appropriate, and why?
- whether Pharmac should delay or avoid a brand change for any of these medicines and, if so, why?
- are there any features of the medicines that we should consider when evaluating them?
- what are the potential benefits, issues, or consequences of dispensing the entire prescription for any of these products all at once?
- are there potential benefits, issues, or consequences if we removed any funding restrictions from the medicine (such as Special Authority criteria)?
- which medicines, indications (uses), or population groups might need an alternative brand if a brand change were to occur and why?
- are the proposed Additional Special Terms for intra-uterine devices [Non-hormonal] (IUDs) appropriate?

We welcome any other feedback you may wish to provide. Please contact us if you wish to discuss anything in this consultation.

We are also seeking feedback from suppliers and people who take medicines.

- [Industry consultation](#)
- [Consultation for the public](#)

Please share this consultation with others who you think might be interested. We want to hear feedback from a range of people.

## About the tender

Pharmac's annual tender is used to contract for supply of medicines. Most of these medicines are already funded in New Zealand and are no longer under patent.

The tender helps to secure the ongoing supply of medicines and generates savings. These savings can be used to fund new medicines. Each year, some of the medicines on the Pharmaceutical Schedule (the list of funded medicines) are included in the annual tender. Although the tender is run annually, the list of medicines included in it changes from year to year. Typically, each medicine is tendered every three years.

Before we run the tender each year, we seek feedback from healthcare professionals, consumer groups, the pharmaceutical industry and the public. This can tell us if:

- tendering is appropriate for each medicine
- there are any potential issues when considering a change in brand for a particular medicine

We get expert advice from Pharmac's [Tender Clinical Advisory Committee](#) advice on every tender decision we make. The committee is made up of healthcare professionals, including doctors, nurse practitioners, and pharmacists. We'll also seek additional advice from specialists in particular fields, such as cancer or mental health, as needed.

The feedback and advice we get makes sure our decision support New Zealanders to live longer, healthier lives.

## What the tender means

If we award a tender for a medicine to a pharmaceutical supplier, then that supplier's brand becomes the principal funded brand of that medicine. It would likely be the only brand of that medicine funded on the Pharmaceutical Schedule (Principal Supply Status). For this tender round, Principal Supply Status would be in place until 30 June 2028.

If the brand awarded the tender was already the only funded brand, there would be no noticeable difference for most people, although the price that Pharmac pays may change.

If that brand was one of multiple funded brands, we would transition from the various funded brands to the brand that has been awarded the tender (and therefore would have Principal Supply Status) over time. The other brands would be removed from the Pharmaceutical Schedule. Usually, this transition lasts for five months.

If that brand was not already funded, we would transition from the old brand to the new one over time. The new brand is listed on the Pharmaceutical Schedule, and there is then a period of time when both the old and new brands would be available and funded. The old brand is then removed from the Pharmaceutical Schedule. Usually, this transition lasts for five months. We notify of any upcoming changes at least one month before any changes occur.

## Access to other brands if a tender is awarded to a new brand

Most people will start on, or transition to, the new brand easily. However, we understand that people's experiences when taking medicines may be different. We use an "alternative brand allowance" (ABA) to support people who may experience, or are at heightened risk of, adverse outcomes from a brand change. This may mean:

- moving back to the old brand after adverse side effects
- having a longer time period of time in which to change brands
- allowing some patients to avoid switching altogether.

The structure of the tender gives Pharmac the flexibility to fund alternative brands in different ways. For example:

- in hospitals, we expect to continue to use the alternative brand allowance provisions in the Schedule. This lets hospitals purchase alternative brands up to a certain percent of volume, typically 5 percent
- in the community, alternative brands could be funded through listing (or maintaining the listing of) other brands under strict Special Authority criteria, or
- managing case-by case approvals through our Exceptional Circumstances framework.

While Pharmac can fund alternative brands, continued supply of a particular alternative brand cannot always be guaranteed. It is helpful to understand what products might need access to alternative brands before we run the tender.

We are keen to understand:

- which medicines, indications, or population groups might need funding for an alternative brand, and if so, why?
- are there any particular features of the products that we should be considering when evaluating potential products?

## Other potential changes

The tender can result in substantial price reductions, and we can use the savings to fund new medicines. We also use the savings to fund changes to the tendered products. For example:

- If the product is currently partially funded, it could become fully funded if the tender was awarded.
- The product could be added to the all-at-once ('stat') dispensing list, which would mean that people could collect prescriptions all at once, rather than monthly.

- We might change or remove funding restrictions so more people can use it (for example, a Special Authority restriction, endorsement, or prescriber-type restriction). We might consult on this separately before making a decision.

We are interested in your feedback on potential changes for the medicines we are tendering. You can see the Pharmaceutical Schedule for all dispensing and funding restrictions: <https://pharmac.govt.nz/pharmaceutical-schedule>

## Additional Special Terms

We have included Additional Special Terms in the draft 2024/25 Invitation to Tender contract for intra-uterine devices [Non-hormonal] (IUDs). This clause would require that potential suppliers offer education, training, and support resources to safely use the supplier's IUD product. This could include a description of the inserter and IUD materials and insertion instructions.

Any feedback on these Additional Special Terms will help inform the final contract.

### *Intra-uterine device (Non-hormonal)*

*You shall provide the following information when submitting a Tender Bid for the Pharmaceutical intra-uterine device [Non-hormonal] (IUD Tender Item):*

- *the size of the IUD Tender Item, including length and width measurements as well as the diameter of the inserter;*
- *a description of the material the inserter is made of;*
- *the duration of the therapeutic effect of the IUD Tender Item; and*
- *the metals which are contained in the IUD Tender Item.*

*You shall provide the following Resources at no cost for the IUD Tender Item:*

- *the provision of education, training and support to healthcare professionals in respect of the use of the IUD Tender Item.*

*For the purposes of this clause "Resources" shall include but not be limited to the:*

- *provision of training materials (DVDs, pamphlets, leaflets, brochures) to healthcare professionals;*
- *provision of an information sheet explaining the differences between the current brand of intra-uterine device and your IUD Tender Item; and*
- *provision of presentations and/or demonstrations on the use of your IUD Tender Item to patients and/or healthcare professionals.*

## The tender list

See **Schedule Two: Products to be tendered (draft, by therapeutic group)** for the list of medicines that we are proposing to include in this year's tender. Medicines have been grouped according to the therapeutic group classification system used in the Pharmaceutical Schedule.

Below is a list of these groups, and the corresponding page numbers. Medicines with multiple indications only appear in one group.

Therapeutic group	Pages
Alimentary Tract and Metabolism	8 - 9
Blood and Blood Forming Organs	9
Cardiovascular System	10 - 11
Dermatologicals	11
Genito-Urinary System	12
Hormone Preparations	12 - 13
Infections	13 - 14
Musculoskeletal System	14
Nervous System	14 - 17
Oncology and Immunosuppressants	17
Respiratory	17 - 18
Sensory Organs	18
Various	18

Most of the tender items in the tender have been included in the annual tender before. However, we have not previously tendered the following products:

Tendered Item
Cladribine <ul style="list-style-type: none"> <li>• Tab 10 mg</li> </ul>
Desogestrel <ul style="list-style-type: none"> <li>• Tab 75 mcg</li> </ul>
Famotidine <ul style="list-style-type: none"> <li>• Inj 10 mg per ml, 2 ml</li> </ul>
Fingolimod <ul style="list-style-type: none"> <li>• Cap 0.5 mg</li> </ul>
Fulvestrant <ul style="list-style-type: none"> <li>• Inj 50 mg per ml, 5 ml</li> </ul>
Gefitinib <ul style="list-style-type: none"> <li>• Tab 250 mg</li> </ul>
Icatibant <ul style="list-style-type: none"> <li>• Inj 10 mg per ml, 3 ml prefilled syringe</li> </ul>
Nilotinib <ul style="list-style-type: none"> <li>• Cap 150 mg</li> <li>• Cap 200 mg</li> </ul>
Nitisinone <ul style="list-style-type: none"> <li>• Cap 2 mg</li> </ul>

<ul style="list-style-type: none"> <li>• Cap 5 mg</li> <li>• Cap 10 mg</li> </ul>
<p>Pancreatic enzyme</p> <ul style="list-style-type: none"> <li>• Cap 420 mg</li> </ul>
<p>Perindopril arginine with amlodipine</p> <ul style="list-style-type: none"> <li>• Tab perindopril arginine 10 mg with amlodipine 5 mg</li> <li>• Tab perindopril arginine 5 mg with amlodipine 10 mg</li> <li>• Tab perindopril arginine 5 mg with amlodipine 5 mg</li> </ul>
<p>Pirfenidone</p> <ul style="list-style-type: none"> <li>• Cap 267 mg</li> <li>• Tab 801 mg</li> </ul>
<p>Progesterone</p> <ul style="list-style-type: none"> <li>• Cap 200 mg</li> </ul>
<p>Telmisartan with amlodipine</p> <ul style="list-style-type: none"> <li>• Tab 40 mg with amlodipine 10 mg</li> <li>• Tab 40 mg with amlodipine 5 mg</li> <li>• Tab 80 mg with amlodipine 10 mg</li> <li>• Tab 80 mg with amlodipine 5 mg</li> </ul>

## Information provided for each medicine

For each medicine (as defined by chemical name, form, and strength), we have provided where applicable:

- the current subsidy paid per unit (e.g. capsule, tablet, injection) as of 1 July 2024. These values are ex-manufacturer excluding GST
- the number of units funded in the community per year in the year ending 30 June 2024. These may be partially funded or full funded
- an estimate of the annual community-market value based on the current subsidy paid per unit. This is estimated by multiplying the volume of units used in the year ending 30 June 2024 by the current listed unit subsidy as of 1 July 2024
- comments specifically relating to the tender item and/or its current listing on the Pharmaceutical Schedule

## Explanation of terms, symbols, and abbreviations

Most terms and abbreviations used are self-explanatory. “Tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

Symbols used in the draft tender list:

Symbol	Explanation
Underlined	Tender items where there is currently a sole supply or principal supply contract are underlined. The price and subsidy for these items are fixed until 30 June 2025 unless otherwise stated in the comments column, therefore a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).

H	To be tendered for Principal Supply Status (hospital medicines).
PCT	Pharmaceuticals Health New Zealand   Te Whatu Ora hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded product available for this tender item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP). The supplier of the successful tender bid would be required to hold additional stock.
#	A rebate currently exists.

## Key dates

**23 July 2024** – Consultation begins

**3 September 2024** – Consultation closes

**September 2024** –Tender Clinical Advisory Committee meets

**Late October/Early November 2024** – Final Invitation to Tender issued

**January 2025** – Earliest tender results announced

**April 2025** – Earliest listing of new brands

## Providing feedback

Feedback should be provided to the tender analysts via our [online form](#) or by emailing [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

All feedback received before the closing date will be considered by Pharmac’s Board or its delegate before finalising the 2024/25 Invitation to Tender.

## Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). We will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. Pharmac will give due consideration to any such request.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Ascorbic acid</b>					
Tab 100 mg	7,617,388	\$190,435	\$0.0250	C H 5%	
<b>Bisacodyl</b>					
Tab 5 mg	2,237,753	\$64,895	\$0.0290	C H 5%	
<b>Budesonide</b>					
Cap 3 mg controlled release	461,325	\$449,021	\$0.9733	C H 5%	
<b>Calcitriol</b>					
Cap 0.25 mcg	1,315,678	\$103,807	\$0.0789	C H 5%	
Cap 0.5 mcg	673,334	\$92,112	\$0.1368	C H 5%	
<b>Docusate Sodium with Sennosides</b>					
Tab 50 mg with sennosides 8 mg	70,749,220	\$1,238,111	\$0.0175	C H 5%	
<b>Famotidine</b>					
Inj 10 mg per ml, 2 ml				H 5%	
Inj 10 mg per ml, 4 ml	14,808			C H 5%	Note this is currently listed Cost Brand Source (CBS).
Tab 20 mg	6,879,699	\$337,793	\$0.0491	C H 5%	
Tab 40 mg	1,111,413	\$114,698	\$0.1032	C H 5%	
<b>Ferrous Sulphate</b>					
Tab long-acting 325 mg	12,331,780	\$1,048,201	\$0.0850	C H 5%	
Oral liq 30 mg (6 mg elemental) per ml	8,971,481	\$235,053	\$0.0262	C H 5%	
<b>Glycerol</b>					
Suppos 2.8/4.0 g	410,206	\$213,102	\$0.5195	C H 5%	
<b>Glycopyrronium bromide</b>					
Inj 0.2 mg per ml, 1 ml	56,173	\$213,457	\$3.8000	C H 5%	
<b>Lactulose</b>					
Oral liq 10 g per 15 ml	179,017,006	\$1,292,503	\$0.0072	C H 5%	
<b>Loperamide hydrochloride</b>					
Cap 2 mg	11,497,954	\$208,458	\$0.0181	C H 5%	
<b>Multivitamins</b>					
Tab (BPC cap strength)				H 5%	
<b>Nitisione</b>					
Cap 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 2 mg				H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<b>Omeprazole</b>					
Inf 40 mg				@ H 5%	
Inj 40 mg	9,152	\$68,420	\$7.4760	@ C H 5%	
<b>Pancreatic enzyme</b>					
Cap 150 mg	2,666,338	\$931,352	\$0.3493	C H 5%	Pharmac would consider bids which contain the ranges of 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-600 BP u protease.
Cap 175 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the ranges of 20,000-25,000 BP u lipase, 22,500 BP u amylase and 1250 BP u protease.
Cap 300 mg	6,765,513	\$6,385,291	\$0.9438	C H 5%	Pharmac would consider bids which contain the range of 24,000-25,000 BP u lipase, 18,000 BP u amylase and 1,000-1,500 BP u protease.



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

Chemical Name Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
<b>Pancreatic enzyme</b>						
Cap 420 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the range of 25,000-26,000 BP u lipase, 35,000 BP u amylase and 1,000-1,600 BP u protease.
<b>Pantoprazole</b>						
Tab EC 20 mg	13,913,843	\$307,635	\$0.0221	C H	5%	
Tab EC 40 mg	12,112,347	\$368,700	\$0.0304	C H	5%	
<b>Sodium citrate with sodium lauryl sulphoacetate</b>						
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	518,020	\$371,835	\$0.7178	C H	5%	
<b>Thiamine Hydrochloride</b>						
Tab 50 mg	13,603,330	\$632,555	\$0.0465	C H	5%	

**Blood and Blood Forming Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
<b>Clopidogrel</b>						
Tab 75 mg	15,231,029	\$919,345	\$0.0604	@	C H	5%
<b>Compound electrolytes</b>						
Powder for soln for oral use	2,917,049	\$555,990	\$0.1906		C H	5% Units and unit subsidy expressed as 'per sachet'. There may be a preference for products to include a measuring device or to come in unit dose sachets. Preference for pack sizes of 10-20 sachet packs.
<b>Compound electrolytes with glucose [dextrose]</b>						
Soln with electrolytes	82,650,000	\$539,705	\$0.0065		C H	5% Suppliers may submit tender bids that include one or more flavours of compound electrolytes with glucose soln. Please note product excipients for each flavour in tender bid.
<b>Dipyridamole</b>						
Tab or Cap long-acting 150 mg	1,100,184	\$255,430	\$0.2322		C H	5%
<b>Heparin Sodium</b>						
Inj 5,000 iu per ml, 5 ml	12,777	\$106,049	\$8.3000		C H	5%
<b>Long-acting filgrastim</b>						
Inj 6 mg per 0.6 ml	12,971	\$843,115	\$65.0000		C H	5% Units displayed as per listed pegfilgrastim.
<b>Plerixafor</b>						
Inj 20 mg per ml, 1.2 ml vial				#	H	5%
<b>Sodium chloride</b>						
inj 0.9%, 10 ml, prefilled syringe					H	5%
inj 0.9%, 3 ml, prefilled syringe					H	5%
inj 0.9%, 5 ml, prefilled syringe					H	5%
Inj 0.9%, 5 ml	104,558	\$20,912	\$0.2000		C H	5%
Inj 0.9%, 10 ml	566,764	\$59,510	\$0.1050		C H	5%
Inj 0.9%, 20 ml	183,827	\$45,957	\$0.2500		C H	5%
<b>Tenecteplase</b>						
Inj 50 mg					H	5%
<b>Tranexamic acid</b>						
Tab 500 mg	3,918,163	\$682,426	\$0.1742		C H	5%
<b>Water for Injection</b>						
Purified for inj, 10 ml	387,274	\$58,866	\$0.1520		C H	5%
Purified for inj, 20 ml	46,716	\$11,679	\$0.2500		C H	5%

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Amiodarone hydrochloride</b>					
<u>Inj 50 mg per ml, 3 ml</u>	13,778	\$20,970	\$1.5220	C H 5%	
<u>Tab 100 mg</u>	546,697	\$63,597	\$0.1163	C H 5%	
<u>Tab 200 mg</u>	1,251,234	\$187,272	\$0.1497	C H 5%	
<b>Chlorthalidone [Chlorthalidone]</b>					
<u>Tab 25 mg</u>	6,433,118	\$894,203	\$0.1390	C H 5%	
<b>Clonidine</b>					
<u>Tab 25 mcg</u>	5,277,217	\$1,381,523	\$0.2618	C H 5%	
<b>Digoxin</b>					
<u>Tab 250 mcg</u>	731,289	\$51,497	\$0.0704	C H 5%	
<u>Tab 62.5 mcg</u>	7,702,705	\$250,338	\$0.0325	C H 5%	
<b>Diltiazem hydrochloride</b>					
<u>Cap long-acting 120 mg</u>	7,191,559	\$939,937	\$0.1307	C H 5%	
<b>Enalapril</b>					
<u>Tab 5 mg</u>	3,503,255	\$68,103	\$0.0194	C H 5%	
<u>Tab 10 mg</u>	3,698,474	\$80,960	\$0.0219	C H 5%	
<u>Tab 20 mg</u>	4,631,211	\$120,921	\$0.0261	C H 5%	
<b>Furosemide [Frusemide]</b>					
<u>Inj 10 mg per ml, 2 ml</u>	14,769	\$7,089	\$0.4800	C H 5%	
<b>Iloprost</b>					
<u>Nebuliser soln 10 mcg per ml, 2 ml</u>	12,100	\$74,629	\$6.1677	C H 5%	
<b>Labetalol</b>					
<u>Tab 100 mg</u>	1,045,584	\$151,610	\$0.1450	C H 5%	
<u>Tab 200 mg</u>	674,177	\$182,028	\$0.2700	C H 5%	
<b>Lisinopril</b>					
<u>Tab 5 mg</u>	4,053,185	\$498,542	\$0.1230	C H 5%	
<u>Tab 10 mg</u>	5,592,709	\$725,207	\$0.1297	C H 5%	
<u>Tab 20 mg</u>	6,936,415	\$1,132,162	\$0.1632	C H 5%	
<b>Losartan with hydrochlorothiazide</b>					
<u>Tab 50 mg with hydrochlorothiazide 12.5 mg</u>	18,467,937	\$2,462,330	\$0.1333	C H 5%	
<b>Nicorandil</b>					
<u>Tab 10 mg</u>	980,039	\$354,941	\$0.3622	C H 5%	
<u>Tab 20 mg</u>	124,486	\$56,931	\$0.4573	C H 5%	
<b>Nifedipine</b>					
<u>Tab long-acting 10 mg</u>	672,399	\$233,181	\$0.3468	C H 5%	
<u>Tab long-acting 20 mg</u>	745,175	\$132,045	\$0.1772	C H 5%	
<u>Tab long-acting 30 mg</u>	601,297	\$205,241	\$0.3413	C H 5%	
<u>Tab long-acting 60 mg</u>	124,224	\$65,603	\$0.5281	C H 5%	
<b>Nimodipine</b>					
<u>Inj 0.2 mg per ml, 50 ml</u>				H 5%	
<u>Tab 30 mg</u>				H 5%	
<b>Noradrenaline</b>					
<u>Inj 1 mg per ml, 4 ml ampoule</u>			@	H 5%	
<b>Perindopril arginine with amlodipine</b>					
<u>Tab perindopril arginine 10 mg with amlodipine 10 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 10 mg with amlodipine 5 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 5 mg with amlodipine 10 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Tab perindopril arginine 5 mg with amlodipine 5 mg</u>				C H 5%	Not currently listed on the Pharmaceutical Schedule.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>			<b>Unit</b>			
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>	
<b>Sotalol</b>						
Tab 80 mg	3,934,967	\$295,123	\$0.0750	C H 5%		
Tab 160 mg	91,880	\$12,863	\$0.1400	C H 5%		
<b>Spirolactone</b>						
Tab 25 mg	11,391,992	\$419,225	\$0.0368	C H 5%		
Tab 100 mg	1,958,678	\$208,599	\$0.1065	C H 5%		
<b>Telmisartan</b>						
Tab 40 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
Tab 80 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
<b>Telmisartan with amlodipine</b>						
Tab 40 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.	
Tab 40 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.	
Tab 80 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.	
Tab 80 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.	

**Dermatologicals**

<b>Chemical Name</b>			<b>Unit</b>			
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>	
<b>Cetomacrogol with glycerol</b>						
<u>Crn 90% with glycerol 10%, 1,000 ml</u>	446,114,500	\$1,561,401	\$0.0035	C H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.	
<u>Crn 90% with glycerol 10%, 500 ml</u>	446,114,500	\$1,561,401	\$0.0035	C H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.	
<b>Clobetasol propionate</b>						
<u>Crn 0.05% (pack size 30 g or less)</u>	3,795,270	\$303,622	\$0.0800	C H 5%		
<u>Oint 0.05% (pack size 30 g or less)</u>	3,787,050	\$294,140	\$0.0777	C H 5%		
<u>Scalp app 0.05%</u>	975,570	\$203,572	\$0.2087	C H 5%		
<b>Clotrimazole</b>						
<u>Crn 1%</u>	2,822,320	\$155,228	\$0.0550	C H 5%		
<b>Dimethicone</b>						
<u>Crn 5% (pack size 100 g or less)</u>				H 5%	Preference for a tube pack.	
<u>Lotn - head lice suffocant</u>	7,469,200	\$158,721	\$0.0213	C H 5%	Preference for a pump bottle.	
<u>Crn 5% (pack size greater than 100 g)</u>	6,238,000	\$53,647	\$0.0086	C H 5%	Preference for a pump bottle.	
<b>Hydrocortisone</b>						
<u>Crn 1% (pack size greater than or equal to 15 g and less than or equal to 100 g)</u>	14,457,652	\$857,772	\$0.0593	C H 5%		
<u>Crn 1% (pack size greater than 100 g)</u>	7,307,095	\$433,530	\$0.0593	C H 5%		
<b>Liquid paraffin with white soft paraffin</b>						
<u>Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)</u>				H 5%		
<u>Liquid paraffin 50% with white soft paraffin 50% ointment (pack size greater than 100 g)</u>	15,818,500	\$156,287	\$0.0099	C 5%		
<b>Sunscreens, proprietary</b>						
<u>SPF 50+ or greater</u>				H 5%		
<b>Zinc and castor oil</b>						
<u>Oint (pack size greater than or equal to 500 g)</u>	22,286,937	\$189,439	\$0.0085	C H 5%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Genito Urinary System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Clotrimazole</b>					
<u>Vaginal crm 1% with applicators</u>	2,013,725	\$201,373	\$0.1000	C H 5%	
<u>Vaginal crm 2% with applicators</u>	1,782,180	\$343,070	\$0.1925	C H 5%	
<b>Desogestrel</b>					
Tab 75 mcg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<b>Ethinylestradiol with levonorgestrel</b>					
<u>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tabs</u>	5,725,495	\$102,257	\$0.0179	C H 5%	
<u>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tabs</u>	20,893,431	\$373,157	\$0.0179	C H 5%	
<b>Intra-uterine device (Non-hormonal)</b>					
IUD Long	2,934	\$87,433	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
IUD Medium	3,666	\$109,247	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
IUD Short	2,951	\$87,940	\$29.8000	C H 5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MRD certification. Special terms will apply see Schedule 5.
<b>Levonorgestrel</b>					
<u>0.75 mg - 1.5 mg</u>	145,587	\$254,777	\$1.7500	C H 5%	Units shown are for tab 1.5 mg.
<b>Oxytocin</b>					
<u>Inj 5 iu per ml, 1 ml</u>	868	\$865	\$0.9960	C H 5%	
<u>Inj 10 iu per ml, 1 ml</u>	6,918	\$8,274	\$1.1960	C H 5%	
<b>Oxytocin with ergometrine</b>					
<u>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml</u>	4,773	\$30,929	\$6.4800	C H 5%	
<b>Tamsulosin</b>					
Tab 400 mcg	6,851,004	\$1,528,459	\$0.2231	C H 5%	

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Carbimazole</b>					
Tab 5 mg	5,408,092	\$408,852	\$0.0756	C H 5%	
<b>Dexamethasone phosphate</b>					
<u>Inj 4 mg per ml, 1 ml</u>	83,070	\$65,293	\$0.7860	C H 5%	Preference for a preservative free product. Pharmac reserves the right to list a preservative free product for a restricted market.
<u>Inj 4 mg per ml, 2 ml</u>	108,097	\$141,607	\$1.3100	C H 5%	Preference for a preservative free product. Pharmac reserves the right to list a preservative free product for a restricted market.
<b>Fludrocortisone Acetate</b>					
Tab 100 mcg	1,723,618	\$197,527	\$0.1146	C H 5%	
<b>Progesterone</b>					
Cap 100 mg	16,504,740	\$8,169,846	\$0.4950	C H 5%	
Cap 200 mg				C H	Not currently listed on the Schedule. Pharmac reserves the right to award one or both presentations of progesterone.
<b>Propylthiouracil</b>					
Tab 50 mg	267,187	\$93,515	\$0.3500	C H 5%	

Principal Sole Supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Testosterone undecanoate</b>					
Cap 40 mg	539,239	\$194,126	\$0.3600	C H 5%	
<b>Infections</b>					
<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Abacavir Sulphate with Lamivudine</b>					
Tab 600 mg with lamivudine 300 mg	113,469	\$111,577	\$0.9833	C H 5%	
<b>Aciclovir</b>					
Tab dispersible 200 mg	565,913	\$40,293	\$0.0712	C H 5%	
Tab dispersible 400 mg	3,669,421	\$380,702	\$0.1038	C H 5%	
Tab dispersible 800 mg	318,565	\$58,798	\$0.1846	C H 5%	
<b>Amoxicillin</b>					
Cap 250 mg	701,404	\$60,952	\$0.0869	@ C H 5%	
Cap 500 mg	19,697,628	\$1,615,205	\$0.0820	@ C H 5%	
<b>Atazanavir Sulphate</b>					
Cap 150 mg	49,252	\$69,774	\$1.4167	C H 5%	
Cap 200 mg	14,156	\$25,953	\$1.8333	C H 5%	
<b>Caspofungin</b>					
Inj 50 mg				H 5%	
Inj 70 mg				H 5%	
<b>Cefaclor monohydrate</b>					
Cap 250 mg	1,262,746	\$326,420	\$0.2585	@ C H 5%	
Grans for oral liq 125 mg per 5 ml	1,833,177	\$68,744	\$0.0375	@ C H 5%	
<b>Cefalexin monohydrate</b>					
Cap 250 mg	441,164	\$84,924	\$0.1925	@ C H 5%	
Cap 500 mg	5,716,867	\$1,672,184	\$0.2925	@ C H 5%	
<b>Ceftriaxone sodium</b>					
Inj 500 mg	11,856	\$9,366	\$0.7900	@ C H 5%	
Inj 1 g	8,137	\$5,842	\$0.7180	@ C H 5%	
Inj 2 g				@ H 5%	
<b>Clindamycin</b>					
Inj 150 mg per ml, 4 ml ampoule	1,520	\$5,335	\$3.5100	C H 5%	
<b>Daptomycin</b>					
Inj 350 mg - 500 mg				H 5%	
<b>Emtricitabine with tenofovir disoproxil</b>					
Tab 200 mg with tenofovir disoproxil 300 mg	1,597,166	\$822,540	\$0.5150	C H 5%	
<b>Erythromycin Lactobionate</b>					
Inj 1 g	252	\$2,520	\$10.0000	@ C H 5%	
<b>Methenamine (hexamine) hippurate</b>					
Tab 1 g	5,611,246	\$1,119,444	\$0.1995	C H 5%	
<b>Phenoxymethylpenicillin (Penicillin V)</b>					
Grans for oral liq 125 mg per 5 ml	152,436	\$5,183	\$0.0340	@ C H 5%	
Grans for oral liq 250 mg per 5 ml	3,401,641	\$144,230	\$0.0424	@ C H 5%	
<b>Piperacillin with Tazobactam</b>					
Inj 2 g with tazobactam 2000/250 mg				H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award one or both presentations of piperacillin with tazobactam.
Inj 4 g with tazobactam 4000/500 mg				H 5%	Pharmac reserves the right to award one or both presentations of piperacillin with tazobactam.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

<b>Chemical Name</b>			<b>Unit</b>			
Line Item	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>		<b>ABA Limit</b>	<b>Comments</b>
<b>Posaconazole</b>						
<u>Oral liq 40 mg per ml</u>	6,384	\$20,825	\$3.2620		C H 5%	
<u>Tab modified-release 100 mg</u>	50,427	\$432,832	\$8.5833		C H 5%	
<b>Raltegravir potassium</b>						
Tab 400 mg	75,037	\$1,363,197	\$18.1670#		C H 5%	
Tab 600 mg	113,986	\$2,070,784	\$18.1670#		C H 5%	
<b>Tenofovir disoproxil</b>						
<u>Tab 300 mg</u>	484,426	\$1,726,010	\$3.5630		C H 5%	
<b>Trimethoprim with sulphamethoxazole [Co-trimoxazole]</b>						
Oral liq trimethoprim and sulphamethoxazole	6,053,438	\$302,672	\$0.0500		C H 5%	
<b>Voriconazole</b>						
<u>Inj 200 mg vial</u>					H 5%	

**Musculoskeletal System**

<b>Chemical Name</b>			<b>Unit</b>			
Line Item	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>		<b>ABA Limit</b>	<b>Comments</b>
<b>Colchicine</b>						
<u>Tab 500 mcg</u>	5,156,056	\$309,363	\$0.0600		C H 5%	Preference for blister packaging.
<b>Risedronate sodium</b>						
<u>Tab 35 mg</u>	324,189	\$202,618	\$0.6250		C H 5%	
<b>Rocuronium bromide</b>						
<u>Inj 10 mg per ml, 5 ml</u>				@	H 5%	
<b>Tenoxicam</b>						
<u>Tab 20 mg</u>	322,443	\$59,652	\$0.1850		C H 5%	
<b>Teriparatide (current access)</b>						
<u>Inj 250 mcg per ml</u>	4,193	\$817,635	\$195.0000		C H 5%	Pharmac would only award a tender for current or widened access.
<b>Teriparatide (widened access)</b>						
Inj 250 mcg per ml					C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for clinical vertebral fractures.
<b>Zoledronic acid</b>						
<u>Inj 5 mg</u>	2,278	\$35,651	\$15.6500		C H 5%	

**Nervous System**

<b>Chemical Name</b>			<b>Unit</b>			
Line Item	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>		<b>ABA Limit</b>	<b>Comments</b>
<b>Bupivacaine hydrochloride with fentanyl</b>						
<u>Inj 1.25mg with 2 mcg fentanyl per ml, 100 ml bag</u>					H 5%	Preference for a product with sterile packaging.
<u>Inj 1.25mg with 2 mcg fentanyl per ml, 200 ml bag</u>					H 5%	Preference for a product with sterile packaging.
<b>Bupivacaine hydrochloride with glucose</b>						
<u>Inj 0.5% with glucose 8%, 4 ml ampoule</u>					H 5%	
<b>Buprenorphine with Naloxone</b>						
<u>Tab sublingual 2 mg with naloxone 0.5 mg</u>	619,564	\$260,217	\$0.4200		C H 5%	
<u>Tab sublingual 8 mg with naloxone 2 mg</u>	558,140	\$677,744	\$1.2143		C H 5%	
<b>Citalopram hydrobromide</b>						
<u>Tab 20 mg</u>	28,019,860	\$954,076	\$0.0341		C H 5%	
<b>Cladribine</b>						
Tab 10 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Codeine phosphate</b>					
Tab 15 mg	10,827,145	\$640,967	\$0.0592	C H 5%	
Tab 30 mg	23,189,568	\$1,618,632	\$0.0698	C H 5%	
Tab 60 mg	1,462,191	\$203,098	\$0.1389	C H 5%	
<b>Cyclizine lactate</b>					
Inj 50 mg per ml, 1 ml ampoule	90,106	\$147,413	\$1.6360	C H 5%	
<b>Dihydrocodeine tartrate</b>					
Tab long-acting 60 mg	3,738,002	\$535,768	\$0.1433	C H 5%	
<b>Domperidone</b>					
Tab 10 mg	9,300,597	\$372,024	\$0.0400	C H 5%	
<b>Droperidol</b>					
Inj 2.5 mg per ml, 1 ml ampoule				H 5%	
<b>Fingolimod</b>					
cap 0.5 mg	116,696	\$9,168,972	\$78.5714#	C H 5%	
<b>Fluoxetine hydrochloride</b>					
Cap 20 mg	24,560,267	\$854,206	\$0.0348	C H 5%	
Tab dispersible 20 mg, scored	1,851,260	\$165,299	\$0.0893	C H 5%	
<b>Levomopromazine</b>					
Inj 25 mg per ml, 1 ml	100,900	\$247,003	\$2.4480 @	C H 5%	
<b>Lidocaine [Lignocaine]</b>					
Gel 2%, 10 ml - 11 ml urethral syringe	125,950	\$749,403	\$5.9500	C H 5%	Units shown are for 11ml urethral syringe.
<b>Lidocaine [lignocaine] hydrochloride</b>					
Spray 10 mg dose per spray				H 5%	
Gel 2%	4,832,127	\$1,063,068	\$0.2200	C H 5%	Tender is for topical gel, not urethral syringe.
<b>Lidocaine [lignocaine] hydrochloride with adrenaline</b>					
Inj 1% with adrenaline 1:100,000, 5 ml				H 5%	
<b>Lithium carbonate</b>					
cap 250 mg	2,895,703	\$647,479	\$0.2236	C H 5%	
<b>Methadone hydrochloride</b>					
Tab 5 mg	1,919,217	\$278,287	\$0.1450	C H 5%	
<b>Methylphenidate hydrochloride (current access)</b>					
Cap modified-release 10 mg	1,531,183	\$796,215	\$0.5200	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 20 mg	1,842,553	\$1,252,936	\$0.6800	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 30 mg	1,165,954	\$991,760	\$0.8506	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 40 mg	910,091	\$928,293	\$1.0200	C H 5%	Pharmac would only award a tender for current or widened access.
Cap modified-release 60 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
<b>Methylphenidate hydrochloride (widened access)</b>					
Cap modified-release 10 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 20 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 30 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Methylphenidate hydrochloride (widened access)</b>					
Cap modified-release 40 mg				C H 5%	Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
Cap modified-release 60 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access. Widened access would be for as a first line treatment for ADHD.
<b>Metoclopramide hydrochloride</b>					
<u>Inj 5 mg per ml, 2 ml ampoule</u>	144,975	\$101,483	\$0.7000	C H 5%	
<b>Morphine</b>					
<u>Inj 10 mg per ml, 1 ml</u>	232,203	\$217,342	\$0.9360 @	C H 5%	
<u>Inj 15 mg per ml, 1 ml</u>	5,700	\$6,304	\$1.1060 @	C H 5%	
<u>Inj 30 mg per ml, 1 ml</u>	60,722	\$76,267	\$1.2560 @	C H 5%	
<u>Inj 5 mg per ml, 1 ml</u>	70,586	\$75,951	\$1.0760 @	C H 5%	
<b>Morphine sulphate</b>					
<u>Cap long-acting 10 mg</u>	4,189,681	\$1,256,904	\$0.3000	C H 5%	
<u>Cap long-acting 30 mg</u>	1,035,437	\$445,238	\$0.4300	C H 5%	
<u>Cap long-acting 60 mg</u>	296,410	\$266,769	\$0.9000	C H 5%	
<u>Cap long-acting 100 mg</u>	171,845	\$180,437	\$1.0500	C H 5%	
<b>Nortriptyline hydrochloride</b>					
<u>Tab 10 mg</u>	17,147,538	\$421,829	\$0.0246	C H 5%	
<u>Tab 25 mg</u>	10,039,771	\$350,790	\$0.0349	C H 5%	
<b>Ondansetron</b>					
<u>Tab 4 mg</u>	2,710,410	\$123,053	\$0.0454	C H 5%	
<u>Tab 8 mg</u>	797,465	\$65,392	\$0.0820	C H 5%	
<b>Ondansetron hydrochloride</b>					
<u>Inj 2 mg per ml, 2 ml</u>				H 5%	
<u>Inj 2 mg per ml, 4 ml</u>				H 5%	
<b>Paracetamol</b>					
<u>Oral liq 120 mg per 5 ml</u>	53,237,034	\$1,059,417	\$0.0199	C H 5%	Preference for a product with a syringe included.
<u>Oral liq 250 mg per 5 ml</u>	225,051,604	\$3,769,614	\$0.0168	C H 5%	Preference for a product with a syringe included.
<b>Paracetamol with codeine</b>					
Tab paracetamol 500 mg with codeine phosphate 15 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	43,907,260	\$1,207,450	\$0.0275	C H 5%	
<b>Paroxetine</b>					
<u>Tab 20 mg</u>	9,283,997	\$424,000	\$0.0457	C H 5%	
<b>Pethidine hydrochloride</b>					
<u>Tab 50 mg</u>	153,175	\$132,956	\$0.8680	C H 5%	
<b>Pramipexole hydrochloride</b>					
<u>Tab 0.25 mg</u>	2,119,168	\$116,766	\$0.0551	C H 5%	
<u>Tab 1 mg</u>	195,533	\$36,486	\$0.1866	C H 5%	
<b>Propofol</b>					
<u>Inj 10 mg per ml, 100 ml</u>			@	H 5%	
<u>Inj 10 mg per ml, 20 ml</u>			@	H 5%	
<u>Inj 10 mg per ml, 50 ml</u>			@	H 5%	
<b>Ropinirole hydrochloride</b>					
<u>Tab 0.25 mg</u>	1,785,561	\$86,082	\$0.0482	C H 5%	
<u>Tab 1 mg</u>	1,008,517	\$59,432	\$0.0589	C H 5%	
<u>Tab 2 mg</u>	358,570	\$27,660	\$0.0771	C H 5%	

Principal Sole Supply

#=rebate \*=part charge @=ASP +=patent



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Ropinirole hydrochloride</b>					
Tab 5 mg	30,035	\$5,185	\$0.1726	C H 5%	
<b>Sertraline</b>					
Tab 50 mg	25,120,860	\$828,988	\$0.0330	C H 5%	
Tab 100 mg	12,082,200	\$700,768	\$0.0580	C H 5%	
<b>Sumatriptan</b>					
Inj 12 mg per ml, 0.5 ml	50,788	\$756,741	\$14.9000	C H 5%	
<b>Tetrabenazine</b>					
Tab 25 mg	116,988	\$111,337	\$0.9517	C H 5%	

**Oncology Agents and Immunosuppressants**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Azathioprine</b>					
Tab 50 mg	3,949,005	\$319,869	\$0.0810	C H 5%	Preference for blister packaging.
Tab 25 mg	490,446	\$60,163	\$0.1227	C H 5%	Preference for blister packaging.
<b>Bortezomib</b>					
Inj 3.5 mg				PCT H 5%	
<b>Capecitabine</b>					
Tab 150 mg	130,094	\$21,248	\$0.1633	C H 5%	
Tab 500 mg	709,762	\$275,033	\$0.3875	C H 5%	
<b>Carmustine</b>					
Inj 100 mg vial				PCT H 5%	
<b>Fludarabine phosphate</b>					
Inj 50 mg				PCT H 5%	
Tab 10 mg	2,299	\$47,359	\$20.6000	PCT C H 5%	
<b>Fulvestrant</b>					
Inj 50 mg per ml, 5 ml	6,630	\$3,540,420	\$534.0000#	C H 5%	
<b>Gefitinib</b>					
Tab 250 mg	15,075	\$461,295	\$30.6000#	C H 5%	
<b>Mercaptopurine</b>					
Tab 50 mg	467,426	\$484,253	\$1.0360	PCT C H 5%	
<b>Mitomycin C</b>					
Inj 2 mg - 5 mg				PCT H 5%	
Inj 10 mg - 20 mg				PCT H 5%	
<b>Nilotinib</b>					
Cap 150 mg	52,432	\$2,044,848	\$39.0000#	C H 5%	
cap 200 mg	52,264	\$2,844,904	\$54.4333#	C H 5%	

**Respiratory System and Allergies**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Adrenaline autoinjector</b>					
Inj 0.15 mg per 0.3 ml	7,269	\$654,210	\$90.0000	C H 5%	
Inj 0.3 mg per 0.3 ml	26,600	\$2,394,000	\$90.0000	C H 5%	
<b>Caffeine citrate</b>					
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml				H 5%	
Oral liq 20 mg per ml (10 mg base per ml)	12,657	\$10,189	\$0.8050	C H 5%	
<b>Icatibant</b>					
Inj 10 mg per ml, 3 ml prefilled syringe	930	\$2,481,240	\$2,668.0000#	C H 5%	
<b>Loratadine</b>					
Tab 10 mg	40,228,419	\$716,066	\$0.0178	C H 5%	

Principal Sole Supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Respiratory System and Allergies**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Montelukast</b>					
Tab 10 mg	2,346,098	\$242,985	\$0.1036	C H 5%	
Tab 4 mg	257,899	\$28,552	\$0.1107	C H 5%	
Tab 5 mg	419,283	\$46,419	\$0.1107	C H 5%	
<b>Nintedanib</b>					
Cap 100 mg	39,840	\$1,695,869	\$42.5670#	C H 5%	
Cap 150 mg	92,040	\$5,936,580	\$64.5000#	C H 5%	
<b>Pirfenidone</b>					
Cap 267 mg				C H 5%	
tab 801 mg	83,184	\$3,368,952	\$40.5000#	C H 5%	
<b>Promethazine Hydrochloride</b>					
Tab 10 mg	3,237,752	\$90,009	\$0.0278	C H 5%	
Tab 25 mg	5,870,176	\$185,498	\$0.0316	C H 5%	

**Sensory Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Chloramphenicol</b>					
Eye drops 0.5%	1,652,170	\$239,565	\$0.1450	C H 5%	Units are expressed per ml.
Eye oint 1%	723,600	\$157,745	\$0.2180	C H 5%	
<b>Olopatadine</b>					
Eye drops 0.1%	1,567,315	\$680,215	\$0.4340	C H 5%	For products containing Benzalkonium chloride (BAK), Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
<b>Sodium cromoglicate</b>					
Eye drops 2%	419,690	\$109,959	\$0.2620	C H 5%	Units are expressed per ml.
<b>Sodium hyaluronate [hyaluronic acid]</b>					
Inj 10 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 14 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 18 mg per ml, 0.85 ml syringe				H 5%	
Inj 23 mg per ml, 0.6 ml syringe				H 5%	

**Various**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Sodium Hypochlorite</b> 5% Soln				C 5%	Not currently listed on the Pharmaceutical Schedule. Preference for a child safe bottle.